Aung Tun, MD
Hematology · Westwood, KSNPI 1033508304
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,467 of the $16,585 with a category attached, or 81.2%. ADC Therapeutics America, Inc. accounts for 66.9% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $10,979 and has fallen 60.8% since, to $4,307 in 2025.
Across 57 payments — averaging $290.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ADC Therapeutics America, Inc.$11K
- Acrotech Biopharma Inc.$4K
- Adaptive Biotechnologies Corporation$338
- Novartis$187
- Genentech USA, Inc.$174
- AstraZeneca$164
- plus $754 from 14 others
Across 246 payments — averaging $10,468 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.2M
- Pfizer$343K
- F. Hoffmann-la Roche AG$8K
What the payments were for
- Consulting fees$13,46781%
- Travel & lodging$7595%
- Food & beverage$2,35914%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ADC Therapeutics America, Inc. | 13 | $11,101 |
| Acrotech Biopharma Inc. | 7 | $3,867 |
| Adaptive Biotechnologies Corporation | 3 | $338 |
| Novartis | 10 | $187 |
| Genentech USA, Inc. | 2 | $174 |
| AstraZeneca(2 entities) | 2 | $164 |
| Genentech, Inc. | 2 | $156 |
| Seagen Inc. | 1 | $117 |
| AbbVie | 2 | $74 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $71 |
| Kyowa Kirin, Inc. | 2 | $67 |
| Bristol Myers Squibb | 1 | $64 |
| Merck | 2 | $38 |
| Puma Biotechnology, Inc. | 2 | $31 |
| Dendreon Pharmaceuticals LLC | 1 | $29 |
| GSK | 1 | $24 |
| Genmab U.S., Inc. | 1 | $22 |
| Taiho Oncology, Inc. | 1 | $22 |
| Incyte Corporation | 1 | $20 |
| Sanofi | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few hematology providers in Kansasto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ImbruvicaIbrutinib | 35 | $643,579 |
| BrukinsaZanubrutinib | 28 | $388,200 |
| CalquenceAcalabrutinib Maleate | 19 | $278,843 |
| Bexarotene | 15 | $16,253 |
| Acyclovir | 48 | $1,274 |
| Potassium Chloride | 14 | $374 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 77 | $312 |
| Duloxetine Hcl | 13 | $287 |
| Pantoprazole Sodium | 21 | $283 |
| Gabapentin | 23 | $249 |
| Fluconazole | 14 | $164 |
| Levofloxacin | 14 | $127 |
| Prednisone | 30 | $100 |
| Allopurinol | 11 | $96 |
| Mirtazapine | 13 | $71 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $164 | $278,84319 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few hematology providers in Kansason file to place this against a meaningful peer group, so we don't.
Other hematology in Westwood
- Nausheen AhmedWestwood$61K
- Forat LutfiWestwood$12K
- Alma HabibWestwood$369
- Konstantine HalkidisKansas City$16K
- Barry SkikneKansas City$4K
- Robert KribsKansas City$824
- Edwin PetrikTopeka$779
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.